SUE PHELPS: Open Payments
NPI 1558093484 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,358 in 113 payments from 33 companies in 2025. Trend: 2023 $3,087 · 2024 $7,976 · 2025 $2,358
Food & beverage: $2,259Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $397 |
| Ardelyx, Inc. | 7 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $217 |
| Janssen Biotech, Inc. | 5 | $165 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $162 |
| Boston Scientific Corporation | 2 | $154 |
| Regeneron Healthcare Solutions, Inc. | 5 | $135 |
| GENZYME CORPORATION | 5 | $128 |
| Ipsen Biopharmaceuticals, Inc | 5 | $100 |
| PFIZER INC. | 4 | $73 |
Products named: DUPIXENT, IBSRELA, ENTYVIO, TREMFYA, XIFAXAN, WATCHMAN FLX, RINVOQ, IQIRVO.
Industry payments across GA — which companies pay providers there.
